Alto Neuroscience Quarterly Balance Sheet
NYSE: ANROHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Alto Neuroscience financial position
As of Jun 30, 2026, Alto Neuroscience reported total assets of $254.1 million, up 60.9% from a year earlier against total liabilities of $34.8 million. Shareholders' equity stood at $219.2 million, or 86.3% of assets. The company held $243.7 million in cash and equivalents against $16.2 million of debt, a net cash position of $227.5 million.
The current ratio (current assets divided by current liabilities) was 14.85, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.07.
Summary generated from market data by MetaCap's automated system. Methodology
Alto Neuroscience balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 243.73M | 263.76M | 176.48M | 137.82M | 147.59M | 160.75M | 168.23M | 181.70M | 193.12M | 205.90M | 82.55M | 51.29M |
| Total Current Assets | 247.32M | 269.13M | 177.72M | 139.45M | 149.85M | 163.52M | 169.34M | 183.53M | 195.41M | 208.31M | 85.39M | — |
| Property, Plant & Equipment | 2.05M | 2.23M | 1.87M | 2.03M | 2.31M | 2.48M | 2.67M | 2.35M | 1.44M | 1.55M | 1.11M | — |
| Total Assets | 254.07M | 276.26M | 184.69M | 147.01M | 157.88M | 171.91M | 177.54M | 191.61M | 197.36M | 209.92M | 86.63M | — |
| Accounts Payable | 4.02M | 3.37M | 1.88M | 2.06M | 1.67M | 1.38M | 1.58M | 2.25M | 1.84M | 2.41M | 1.07M | — |
| Short-Term Debt | 3.77M | 2.14M | 585.00K | — | — | — | 0 | 3.53M | 2.32M | 1.15M | 0 | — |
| Total Current Liabilities | 16.65M | 13.12M | 11.32M | 9.04M | 8.13M | 7.26M | 10.01M | 14.02M | 9.84M | 8.01M | 5.61M | — |
| Long-Term Debt | 12.42M | 13.88M | 16.17M | 20.31M | 20.12M | 19.94M | 10.25M | 6.63M | 7.74M | 8.81M | 9.86M | — |
| Total Liabilities | 34.82M | 32.89M | 33.55M | 35.45M | 34.47M | 32.82M | 26.08M | 26.56M | 17.58M | 16.82M | 16.82M | — |
| Shareholders' Equity | 219.25M | 243.37M | 151.14M | 111.56M | 123.41M | 139.10M | 151.46M | 165.05M | 179.78M | 193.10M | -71.67M | -61.10M |
| Retained Earnings | -255.51M | -227.87M | -201.63M | -185.45M | -171.27M | -153.56M | -138.40M | -123.19M | -106.41M | -90.38M | -76.97M | — |
| Total Debt | 16.19M | 16.02M | 16.76M | 20.31M | 20.12M | 19.94M | 10.25M | 10.16M | 10.06M | 9.96M | 9.86M | — |
| Net Cash (Debt) | 227.55M | 247.74M | 159.73M | 117.50M | 127.46M | 140.81M | 157.97M | 171.54M | 183.06M | 195.94M | 72.69M | 51.29M |
| Shares Outstanding | 35.09M | 35.05M | 31.92M | 27.17M | 27.07M | 27.07M | 26.99M | 26.97M | 26.95M | 26.88M | 3.83M | — |
This table shows 12 quarterly periods of Alto Neuroscience's balance sheet, from Q2 2026 back to Q3 2023, across 14 line items including cash & equivalents, total current assets, property, plant & equipment. Values in USD; B = billions, M = millions. Fiscal periods follow ANRO's reporting calendar. What is a balance sheet?